EPO R protein, Human EPO R - FcA Chimera recombinant protein

Alphabetical Listing of Primary Antibodies:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Alphabetical Listing of Proteins:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Peptides \| Secondary Antibodies \| ELISA Kits

Human EPO R - FcA Chimera recombinant protein

Catalog Number: 10-006-220015

Buy EPO R protein -

Size:

Related Product Names:

- EPO R protein; EPO R; Human EPO R - FcA Chimera
- human cell expressed EPO R - FcA Chimera; Erythropoietin receptor (EPO R)

- Gene Information - Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.

Gene Name: EPO R	Gene Name Synonym: N/A
Gi #: 1352738	NCBI Acc #: P11678	Swiss Prot Acc #: P11678
Length (aa): N/A	Mol. Weight (Da): 81040	Chrom Location: N/A

GenWay Biotech supplies human recombinant proteins expressed from human cells (hcx). This protein is expressed from modified human 293 cells, which has the cellular machinery necessary to attach human post-translational modifications (PTMs) to itself. As such, this protein is different from its recombinant form expressed from other species. GenWay utilizes conventional chromatography purification techniques to purify the proteins. No tag-based affinity chromatography techniques are used for ligands. Each protein has purity greater than 95% by silver stain, with most proteins >97% pure.

Source: A DNA sequence encoding the signal peptide and extracellular domain of human Erythropoietin receptor (EPO R, aa 1-250) was fused to the Fc region of human IgG1 (aa 93-330). The chimeric protein was expressed in modified human 293 cells.

Molecular Mass: Erythropoietin receptor (EPO R) - FcB Chimera migrates as a broad band between 50 and 65 kDa on SDS-PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified EPO R - Fc Chimera that has a predicted molecular mass of 52 kDa.

PI: EPO R - FcB separates into a number of glycoforms with a pI between 6.05 and 8.08 on 2D PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified EPO R - Fc that has a predicted pI of 6.4.

Theoretical Sequence: APPPNLPDPK FESKAALLAA RGPEELLCFT ERLEDLVCFW EEAASAGVGP GNYSFSYQLE DEPWKLCRLH QAPTARGAVR FWCSLPTADT SSFVPLELRV TAASGAPRYH RVIHINEVVL LDAPVGLVAR LADESGHVVL RWLPPPETPM TSHIRYEVDV SAGNGAGSVQ RVEILEGRTE CVLSNLRGRT RYTFAVRARM AEPSFGGFWS AWSEPVSLLT PSDLDPRIPK VDKKVEPKSC DKTHTCPPCP APELL

Activity: The ED50 of EPO R - FcB Chimera is typically 0.15-2.5 ng/ml as measured by its ability to neutralize EPO-mediated proliferation of TF-1 cells.

% Carbohydrate: purified EPO R - FcB Chimera consists of 0-20% carbohydrate by weight.

Glycosylation: EPO R - FcB Chimera is N-glycosylated and is probably O-glycosylated.

Reconstitution: It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial.

Purity/Purification: >95%, as determined by SDS-PAGE and visualized by Coomassie Briliant Blue.

Crossreactivity: Human

Format: When reconstituted in 0.5 ml sterile phosphate-buffered saline, the solution will contain 1% human serum albumin (HSA) and 10% trehalose.

Storage: Lyophilized products should be stored at 2 to 8C. Following reconstitution, short-term storage at 4C is recommended, with longer-term storage in aliquots at -18 to -20C. Repeated freeze thawing is not recommended.

Shipping: Products may be shipped on ice pack or dry ice.

TESTING: (secondary reagents and protocols )

1D GEL: ( anti-EPO R protein )

EPO R protein 1D GEL image
EPO R

EPO R PROTEIN TARGET DESCRIPTION:

Synonym Names for EPO R protein: EPO R; human cell expressed EPO R - FcA Chimera; Erythropoietin receptor (EPO R)

Erythropoietin (EPO) regulates erythropoiesis, the differentiation of erythroid progenitor cells into mature red blood cells, and studies involving EPO deficient mice have confirmed that EPO is required for red blood cell development. Specifcally, EPO plays a role in erythroid progenitor cell survival, proliferation and differentiation, and induction of hemoglobin synthesis. EPO also stimulates proliferation of endothelial cells (i.e. it has a pro-angiogenic effect) and B- cells, stimulates megakaryocytopoiesis, and has neurotrophic, neuroprotective and cardioprotective properties. The effects of EPO are exerted through binding to the EPO receptor (EPO R). EPO R is a 508 amino acid type I transmembrane receptor with a molecular weight of 55kDa and contains a potential N-linked glycosylation site. It is predominantly expressed on pluripotent embryonic stem cells and early multipotent hematopoietic cells as well as in other tissues such as brain, spinal cord, kidney, lung and pancreas. The expression of EPO R is downregulated in a number of disease states such as endometriosis, in which relatively low levels of EPO R are detected in the peritoneal lesions of patients with stage I of the disease, and autosomal dominant erythrocytosis, in which a truncated EPO R increases EPO sensitivity and elevates the production of red blood cells. However EPO R expression has also been observed in many human cancers including uterine, ovarian, mammary, colon, lung, and prostate cancers, melanoma, and hematological malignancies such as leukemias. Furthermore, the administration of EPO-EPO R antagonists can inhibit the growth of cancer cells in vivo, suggesting that EPO signalling may facilitate the progression of human malignant disease states. For a recent review please refer to Bartesaghi S, Marinovich M, Corsini, E, Galli CL, Viviani B. (2004) Neurotoxicity 26(5):923-8.

Catalytic Activity: Donor + H2O2 = oxidized donor + 2 H2O.

Cofactor: Binds 1 calcium ion per heterodimer (By similarity).

Cofactor: Binds 1 heme B (iron-protoporphyrin IX) covalently through ester linkages to hydroxylated methyl groups formed auto-catalytically with hydrogen peroxide at the heme C-1 and C-5 positions. The ester linkage to Asp-232 was observed in 30% of the chains.

Subunit: Tetramer of two light chains and two heavy chains.

Human EPO R - FcA Chimera reacts with human.

OMIM: 131399; gene. [NCBI / EBI]
261500; phenotype. [NCBI / EBI]

Products similar to EPO R protein:

IgG

EPO receptor, IgG

SUGGESTED PROTEIN REAGENTS - GenWay offers reagents to facilitate your research with cell-based assays, Mass Spectrometry, standards, calibrators, Western blot, cell culture, antibiotics, microwell substrates, and more!

Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.

Precautions: EPO R protein is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.

Important Notes: During shipment, small volumes of EPO R protein vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.

Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about EPO R protein, all related information, articles, resources about EPO R protein are being stored on our online database. Let us know if you have questions regarding this product.

Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed.

GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.

GenWay has a diverse line of recombinant protein expression platforms, including E. coli expression, Bacliovirus expression, yeast expression, and mammalian expression. Combining the technologies of bioinformatics, protein domain analysis, gene codon optimization, protein fusion, and protein expression in different host cells, GenWay can produce soluble and functional proteins. In particular, GenWay has the capability and vector systems for expression of difficult proteins such as proteases, kinases, glycosylated and membrane proteins. We have a very high success rate (almost 100%) and can deliver the proteins in a timely fashion. This is a core competency necessary for efficient and effective production of immunogens and affinity ligands for antibody production and purification. GenWay has over 300

recombinant proteins

offered in our catalog.



GenWay Biotech, Inc. 6777 Nancy Ridge Drive, San Diego, CA 92121 Tel: (858)458-0866 Fax: (858)458-0833 Email: sales@genwaybio.com www.genwaybio.com ©1998 - 2010 GenWay Biotech, Inc. - All Rights Reserved